ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• ACADIA Pharmaceuticals has received a consensus rating of "Moderate Buy" from eighteen research firms, with an average twelve-month target price of $28.88.
• Insider trading activity included Director Laura Brege selling 14,446 shares at an average price of $21.78, reducing her position by nearly 49%.
• ACADIA's recent earnings report showed an EPS of $0.16, exceeding the estimated $0.14, with a revenue increase of 9.4% year-over-year.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eighteen brokerages that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, ten have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $28.8750.

Several equities analysts recently weighed in on ACAD shares. Morgan Stanley set a $24.00 target price on shares of ACADIA Pharmaceuticals and gave the company an "equal weight" rating in a research note on Tuesday, May 20th. Wall Street Zen upgraded shares of ACADIA Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday. JMP Securities lifted their price objective on shares of ACADIA Pharmaceuticals from $37.00 to $38.00 and gave the company a "market outperform" rating in a report on Thursday, August 7th. Oppenheimer reaffirmed a "market perform" rating and issued a $22.00 price objective (up previously from $19.00) on shares of ACADIA Pharmaceuticals in a research report on Thursday, June 26th. Finally, BMO Capital Markets boosted their target price on shares of ACADIA Pharmaceuticals from $24.00 to $28.00 and gave the stock an "outperform" rating in a research report on Monday, May 19th.

ACADIA Pharmaceuticals Price Performance

ACADIA Pharmaceuticals stock traded down $0.07 during midday trading on Friday, reaching $24.99. 134,256 shares of the company traded hands, compared to its average volume of 2,175,097. The firm has a market capitalization of $4.22 billion, a price-to-earnings ratio of 18.83, a price-to-earnings-growth ratio of 6.45 and a beta of 0.70. The business has a 50 day moving average of $22.77 and a two-hundred day moving average of $19.55. ACADIA Pharmaceuticals has a 12 month low of $13.40 and a 12 month high of $25.88.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.16 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.02. ACADIA Pharmaceuticals had a net margin of 21.80% and a return on equity of 14.69%. The business had revenue of $264.57 million for the quarter, compared to the consensus estimate of $263.07 million. During the same period last year, the firm earned $0.20 earnings per share. The company's quarterly revenue was up 9.4% on a year-over-year basis. As a group, equities analysts forecast that ACADIA Pharmaceuticals will post 0.7 EPS for the current year.

Insider Buying and Selling

In other ACADIA Pharmaceuticals news, Director Laura Brege sold 14,446 shares of the company's stock in a transaction dated Wednesday, June 4th. The shares were sold at an average price of $21.78, for a total value of $314,633.88. Following the transaction, the director owned 15,095 shares of the company's stock, valued at $328,769.10. This represents a 48.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 26.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Exchange Traded Concepts LLC acquired a new stake in shares of ACADIA Pharmaceuticals during the first quarter worth about $29,000. Picton Mahoney Asset Management purchased a new stake in shares of ACADIA Pharmaceuticals during the 1st quarter worth approximately $32,000. Banque Transatlantique SA purchased a new stake in shares of ACADIA Pharmaceuticals during the 1st quarter worth approximately $31,000. Virtus Fund Advisers LLC purchased a new stake in shares of ACADIA Pharmaceuticals during the 4th quarter worth approximately $39,000. Finally, Federated Hermes Inc. lifted its position in shares of ACADIA Pharmaceuticals by 231.5% during the 1st quarter. Federated Hermes Inc. now owns 2,317 shares of the biopharmaceutical company's stock worth $38,000 after buying an additional 1,618 shares during the last quarter. Institutional investors and hedge funds own 96.71% of the company's stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.